Pharmosa Biopharm Inc is a Taiwan-based company mainly engaged in the research and development of new drugs. The main products include L606, for the treatment of Category I pulmonary arterial hypertension (PAH); L606, for the treatment of Category III pulmonary hypertension caused by interstitial lung disease (PH-ILD); L606, for the treatment of chronic thromboembolic Category IV pulmonary hypertension (CTEPH); L608, for the treatment of Category I pulmonary arterial hypertension (PAH).

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-09-22	NT$32.80	-8.64%	480,741
26-09-21	NT$35.90	+8.79%	618,316
26-09-18	NT$33.00	0.00%	261,102
26-09-17	NT$33.00	+0.76%	153,117
26-09-16	NT$32.75	+1.55%	147,048

End-of-day quote Taipei Exchange

More quotes

End-of-day quote Taipei Exchange 2026-09-22			5-day change	1st Jan Change
32.80 ^TWD	-8.64%		+1.71%	-36.80%

08-14	Pharmosa Biopharm Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
05-15	Pharmosa Biopharm Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

Market Cap	4.24B 134M 117M 110M 100M 188M 12.79B 188M 1.32B 509M 6.53B 502M 491M 21.05B	P/E 2024	-40.1x	P/E 2025	-17.5x
Enterprise Value	3.21B 101M 88.42M 83.11M 75.84M 142M 9.67B 142M 997M 385M 4.94B 380M 372M 15.92B	EV / Sales 2024	31,795,013x	EV / Sales 2025	84,259,475x
Free-Float	58.68%	Yield 2024 *	-	Yield 2025	-

08-14	Pharmosa Biopharm Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
05-15	Pharmosa Biopharm Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
03-13	Pharmosa Biopharm Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
11-07	Pharmosa Biopharm Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
25-08-07	Pharmosa Biopharm Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
25-06-10	Pharmosa Biopharm Inc. Announces Phase I Clinical Trial Results of Inhaled Liposomal Iloprost Selected for Oral Presentation at EULAR 2025	CI
25-05-07	Pharmosa Biopharm Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
25-03-07	Pharmosa Biopharm Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
24-11-14	Pharmosa Biopharm Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	CI
24-10-02	Liquidia Corporation and Pharmosa Biopharm Expand Collaboration to Develop Sustained Release Inhaled Treprostinil	CI
24-08-14	Pharmosa Biopharm Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	CI
24-05-15	Pharmosa Biopharm Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
24-03-28	Pharmosa Biopharm Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

1 day	-8.64%
1 week	+1.71%
Current month	-0.61%
1 month	+1.86%
3 months	-11.35%
6 months	-16.11%
Current year	-36.80%

Pharmosa Biopharm Inc. Stock

Stocks

6875

TW0006875008

Biotechnology & Medical Research

Valuation: Pharmosa Biopharm Inc.

Chart: Pharmosa Biopharm Inc.

Latest news: Pharmosa Biopharm Inc.

Press Releases: Pharmosa Biopharm Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Pharmosa Biopharm Inc.

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

1 week	31.55	36.3
1 month	30.45	36.3
Current year	30.45	53.5
1 year	30.45	65
3 years	30.45	125.5
5 years	30.45	162
10 years	30.45	162

Manager	Title	Age	Since
Pei Kan CEO	Chief Executive Officer	-	2018-03-31
Shu Ping Yang DFI	Director of Finance/CFO	-	2015-05-31
Xiang Fa Liang CTO	Chief Tech/Sci/R&D Officer	-	-

Director	Title	Age	Since
Pei Kan BRD	Director/Board Member	-	2018-06-21
Chien Chih Wang CHM	Chairman	-	2016-06-20
Ko Jui Shih BRD	Director/Board Member	-	2021-10-24

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
PHARMOSA BIOPHARM INC.	-8.64%	+1.71%	-29.31%	-63.84%	134M
LONZA GROUP AG	+2.55%	+4.77%	+4.07%	+32.02%	47.86B
IQVIA HOLDINGS INC.	+0.08%	+0.16%	+43.79%	+35.89%	44.46B
BEONE MEDICINES AG	+0.66%	+6.23%	+8.96%	+93.14%	41.85B
REVOLUTION MEDICINES, INC.	+0.05%	-5.86%	+334.27%	+542.87%	41.34B
CELLTRION, INC.	-1.60%	+0.56%	+10.84%	+46.93%	30.04B
MEDPACE HOLDINGS, INC.	+0.96%	+1.56%	+26.52%	+159.67%	17.59B
ASCENDIS PHARMA A/S	-0.01%	-0.92%	-	-	15.6B
EUROFINS SCIENTIFIC SE	+1.15%	+7.46%	+25.97%	+43.93%	15.69B
TEMPUS AI, INC.	-1.08%	+12.11%	-10.11%	-	13.93B
Average	-0.56%	+2.64%	+46.11%	+111.33%	26.85B
Weighted average by Cap.	+0.49%	+2.14%	+68.76%	+143.81%

	2024	2025
Net sales	167.57 5.29 4.62 4.34 3.96 7.44 505.64 7.44 52.14 20.12 258.22 19.86 19.43 832.44	67.27 2.12 1.86 1.74 1.59 2.99 202.98 2.99 20.93 8.08 103.66 7.97 7.8 334.17
Net income	-167M -5.26M -4.6M -4.32M -3.94M -7.4M -503M -7.4M -51.85M -20.01M -257M -19.75M -19.32M -828M	-384M -12.12M -10.59M -9.95M -9.08M -17.04M -1.16B -17.05M -119M -46.09M -591M -45.5M -44.5M -1.91B
Net Debt	-1.5B -47.37M -41.4M -38.91M -35.51M -66.64M -4.53B -66.65M -467M -180M -2.31B -178M -174M -7.46B	-1.03B -32.56M -28.46M -26.75M -24.41M -45.81M -3.11B -45.82M -321M -124M -1.59B -122M -120M -5.12B